Beyenburg S, Bauer J, Reuber M
Department of Neurology, Centre Hospitalier de Luxembourg, 4 rue Barblé, L-1210 Luxembourg.
Postgrad Med J. 2004 Oct;80(948):581-7. doi: 10.1136/pgmj.2004.019976.
The availability of new antiepileptic drugs has broadened the spectrum of medical treatment options in epilepsy. The new agents, together with established drugs, offer substantial choice for doctors treating patients with focal or generalised epilepsy. The newer antiepileptic drugs are not necessarily more effective but usually better tolerated than the traditional agents, mainly because of favourable pharmacokinetic profiles and fewer interactions. Because treatment options have increased, drug therapy can now be tailored to the requirements of individual patients. Nevertheless, significant safety and efficacy issues continue to exist and there is a need for the development of even better agents. This review describes the clinical use of the new antiepileptic drugs, but focuses in particular on monotherapy, the treatment of generalised seizures, teratogenicity, and the cognitive side effect profile of the newer compounds.
新型抗癫痫药物的出现拓宽了癫痫的药物治疗选择范围。这些新药与已有的药物一起,为治疗局灶性或全身性癫痫的医生提供了丰富的选择。新型抗癫痫药物不一定更有效,但通常比传统药物耐受性更好,这主要是因为它们具有良好的药代动力学特性且相互作用较少。由于治疗选择增多,现在可以根据个体患者的需求定制药物治疗方案。然而,重大的安全性和有效性问题仍然存在,因此仍需要研发更好的药物。本综述描述了新型抗癫痫药物的临床应用,但特别关注单药治疗、全身性癫痫发作的治疗、致畸性以及新型化合物的认知副作用情况。